GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) Bundle
Rooted in GuiZhou since 1995, GuiZhou SanLi Pharmaceutical Co., Ltd. combines traditional herbal support for rural livelihoods with modern industry practices-operating two manufacturing sites with a combined annual capacity of 1,500 tons, serving over 3,000 pharmacies and healthcare institutions and holding roughly a 10% share of the local pharmaceutical market; certified under ISO 9001, the company channels about 10% of annual revenue into R&D, grew revenue from 159 million yuan in 2013 to 884 million yuan in 2019 with net profit rising from 19 million yuan to 133 million yuan in the same period, and as of October 9, 2025 boasts a market capitalization near 5.08 billion CNY while pursuing a vision to become a first-class global pharmaceutical enterprise guided by core values-innovation, integrity, cooperation, tolerance and responsibility-plus a customer-focused, quality-first operational ethos.
GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) - Intro
GuiZhou SanLi Pharmaceutical Co., Ltd. is a modern pharmaceutical enterprise founded in 1995, focused on the research, development, production and marketing of medicines across multiple therapeutic areas. The company's product mix includes respiratory system drugs, tonics, gynecological and orthopedic medicines, and cardiovascular & cerebrovascular treatments. Operational scale, quality certification and market reach underpin its strategic positioning within the regional pharmaceutical sector.
- Founded: 1995
- Primary operations: R&D, production, sales
- Therapeutic focus: respiratory, tonic, gynecology, orthopedics, cardio/cerebrovascular
| Metric | Value |
|---|---|
| Manufacturing facilities | 2 (both in Guizhou province) |
| Combined annual production capacity | 1,500 tons of pharmaceutical products |
| Quality certification | ISO 9001 |
| Distribution reach | Over 3,000 pharmacies and healthcare institutions |
| Local market share | ~10% |
| Market capitalization (as of 2025-10-09) | ≈ 5.08 billion CNY |
Mission
- Deliver safe, effective and affordable medicines that improve patient outcomes across respiratory, cardiovascular, gynecological and musculoskeletal conditions.
- Maintain rigorous quality control and compliance (ISO 9001) across R&D and manufacturing to ensure product reliability.
- Support sustainable growth by expanding production capacity, strengthening distribution, and investing in targeted R&D.
Vision
- Be a leading regional pharmaceutical innovator renowned for high-quality generics and targeted therapies.
- Grow market presence from a ~10% local share to a broader national footprint through strategic partnerships and product diversification.
- Leverage manufacturing scale (1,500 tons capacity) and an extensive distribution network (3,000+ endpoints) to improve accessibility of medicines.
Core Values
- Quality first - rigorous adherence to ISO 9001 standards and continuous quality improvement.
- Patient-centeredness - prioritizing safety, efficacy and affordability in product design and delivery.
- Integrity and compliance - transparent governance, regulatory compliance and ethical conduct.
- Innovation and collaboration - focused R&D investments and partnerships to expand therapeutic offerings.
- Operational excellence - efficient manufacturing across two facilities to meet demand reliably.
Strategic Priorities & Performance Indicators
- Capacity utilization: optimize output across 1,500-ton combined capacity to support sales growth.
- Distribution expansion: increase network beyond 3,000 pharmacies and institutions to raise market share above 10%.
- Quality metrics: maintain ISO 9001 compliance and reduce product non-conformance rates through process controls.
- Market valuation: maintain and grow shareholder value from a market capitalization of ≈5.08 billion CNY (2025-10-09) via profitable sales growth and margin improvement.
Further financial and operational insights are discussed in the related analysis: Breaking Down GuiZhou SanLi Pharmaceutical Co.,Ltd Financial Health: Key Insights for Investors
GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) - Overview
Mission Statement- GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) is dedicated to enhancing people's quality of life through perseverance and commitment to health.
- The company emphasizes innovation, allocating approximately 10% of its annual revenue to research and development to drive continuous improvement in its product offerings.
- GuiZhou SanLi adheres to stringent quality control measures, holding ISO 9001 certification to ensure high manufacturing standards.
- Committed to affordability and accessibility, the company prioritizes making essential medications available to broader populations, aligning commercial strategy with public health goals.
- Active local engagement includes supporting Chinese herbal medicine plantation, aiding poverty-stricken farmers, and promoting rural industries to foster regional socioeconomic development.
- To be a leading, trusted pharmaceutical enterprise in China that blends traditional herbal expertise with modern pharmaceutical innovation.
- To expand access to high-quality, affordable medicines domestically and to build capabilities for selective international outreach.
- To continually elevate R&D and manufacturing standards so that product efficacy, safety, and cost-effectiveness drive long-term public health impact.
- Patient-first: prioritizing safety, efficacy, and accessibility in all product decisions.
- Innovation: sustained R&D investment (~10% of annual revenue) to develop and improve therapeutics.
- Quality & Compliance: ISO 9001-certified processes and strict quality-control systems.
- Community Responsibility: direct support for herbal plantation, farmer income initiatives, and rural industrialization.
- Integrity & Transparency: financial discipline and accountable governance to support sustainable growth.
| Metric | 2013 | 2019 | Compound Annual Growth Rate (2013-2019) |
|---|---|---|---|
| Revenue (CNY million) | 159 | 884 | ~33.1% CAGR |
| Net Profit (CNY million) | 19 | 133 | ~38.3% CAGR |
| R&D Investment (% of Revenue) | - | ~10% | - |
| Quality Certification | ISO 9001 | ISO 9001 | - |
- R&D focus: sustaining ~10% revenue allocation to accelerate new product pipelines and formulation improvements while integrating traditional Chinese herbal knowledge with modern pharmacology.
- Manufacturing excellence: continuous strengthening of ISO 9001-aligned quality systems to reduce batch variability and ensure regulatory compliance.
- Access & affordability: pricing strategies and production efficiencies aimed at lowering unit costs for essential medicines to reach underserved populations.
- Rural development programs: procurement and technical support for herbal medicine plantations, targeted subsidies and training for poverty-alleviation beneficiaries, and investments that bolster local agro-pharmaceutical value chains.
- Revenue growth: increased from CNY 159 million (2013) to CNY 884 million (2019), reflecting strong commercial traction and scaling of core product lines.
- Profitability improvement: net profit rose from CNY 19 million (2013) to CNY 133 million (2019), indicating margin expansion alongside volume growth and cost control.
- R&D intensity: maintaining roughly 10% of revenue for R&D positions the company above many domestic peers in reinvestment rate, supporting sustainable innovation.
- Quality assurance: ISO 9001 certification underpins manufacturing reliability and supports regulatory approvals and market trust.
GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) - Mission Statement
GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) positions its mission around delivering high-quality pharmaceuticals, advancing public health, and driving sustainable, innovation-led growth to become a first-class enterprise in the global pharmaceutical and healthcare markets. Vision Statement GuiZhou SanLi's stated vision reiterates its ambition to be a globally admired international pharmaceutical enterprise with sustainable development. The company emphasizes elevating R&D, scaling manufacturing excellence, expanding international market presence, and creating long-term shareholder and societal value. Strategic pillars supporting the vision- Innovation-led R&D: prioritize new drug development, biosimilars, and improved traditional medicine formulations.
- Quality and compliance: align manufacturing to international GMP standards to access regulated markets.
- Global expansion: enter and scale in ASEAN, MENA, and selected developed markets through partnerships and exports.
- Sustainable operations: reduce environmental footprint, optimize supply chains, and invest in employee development.
| Dimension | Target / KPI | Rationale |
|---|---|---|
| Revenue growth | Mid-to-high single digit to double digit CAGR over 3-5 years | Fuel reinvestment into R&D and capacity expansion |
| R&D intensity | R&D spend as % of revenue: aim to increase year-on-year | Build proprietary pipelines and competitive differentiation |
| Export ratio | Increase share of international sales to diversify markets | Reduce domestic concentration risk and capture higher-growth regions |
| Compliance | Maintain clean regulatory record; pass GMP audits for all major facilities | Enable market access and premium pricing |
- Patient-first: prioritize safety, efficacy, and access to essential medicines.
- Integrity: adhere to ethical commercial practices and transparent governance.
- Collaboration: work with academic, clinical, and industry partners to accelerate innovation.
- Responsibility: commit to environmental stewardship and community health initiatives.
- Targeted capital allocation: balance CAPEX for manufacturing and consistent R&D investment to sustain pipeline development.
- Portfolio optimization: shift toward higher-margin therapeutic products and innovative formulations.
- M&A and licensing: pursue selective acquisitions or licensing to fill strategic gaps and accelerate international entry.
- Commercial excellence: strengthen salesforce capabilities, digital marketing, and channel partnerships in key markets.
GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) - Vision Statement
GuiZhou SanLi Pharmaceutical Co., Ltd. envisions becoming a leading, innovation-driven and responsibly governed pharmaceutical group in China and globally, delivering high-quality, affordable medicines while strengthening healthcare ecosystems in underserved regions. The company aligns long-term strategic goals with measurable operational targets to accelerate R&D, broaden production capacity, and deepen market penetration across hospital and retail channels. GuiZhou SanLi Pharmaceutical Co., Ltd. upholds the core values of innovation, integrity, cooperation, tolerance, and responsibility. The company emphasizes quality first, integrity foremost, customer orientation, sincere service, team collaboration, and efficient execution. GuiZhou SanLi is committed to quality first, integrity foremost, customer orientation, sincere service, team collaboration, and efficient execution. The company emphasizes quality first, integrity foremost, customer orientation, sincere service, team collaboration, and efficient execution. GuiZhou SanLi upholds the core values of innovation, integrity, cooperation, tolerance, and responsibility. The company emphasizes quality first, integrity foremost, customer orientation, sincere service, team collaboration, and efficient execution.- Innovation - sustain double-digit annual growth in new product approvals and increase R&D pipeline breadth.
- Integrity - maintain GMP compliance and strengthen pharmacovigilance and regulatory transparency.
- Cooperation - expand strategic partnerships with research institutes and regional distributors.
- Tolerance - foster an inclusive culture that values diverse expertise and patient-focused design.
- Responsibility - prioritize patient safety, environmental stewardship, and community healthcare initiatives.
- Customer orientation - align product development and service processes to end-user needs across hospital and retail channels.
- Team collaboration & efficient execution - optimize cross-functional project delivery, reducing time-to-market for priority projects.
| Metric | 2023 Actual (CNY) | 2022 Actual (CNY) | Target 2024 (CNY) |
|---|---|---|---|
| Revenue | 1,050,000,000 | 980,000,000 | 1,180,000,000 |
| Net Profit (attributable) | 120,000,000 | 110,000,000 | 150,000,000 |
| R&D Expenditure | 45,000,000 | 38,000,000 | 60,000,000 |
| Total Assets | 2,300,000,000 | 2,150,000,000 | 2,500,000,000 |
| Employees (end-year) | 2,400 | 2,300 | 2,600 |
| Current Ratio | 1.6 | 1.5 | 1.7 |
- Quality & Compliance targets - maintain zero major GMP citations; reduce product complaint rate by 20% year-on-year.
- R&D targets - progress at least 2 clinical-stage candidates or four IND filings within 24 months.
- Market expansion - increase hospital penetration in 6 new provinces and grow OTC/retail channel sales by 25%.
GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.